## PFE: Pfizer, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.5% below STRENGTH zone (4.0-10.0%); PEG 3.77 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($24.13)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Pfizer Inks About $2 Bln Exclusive Deal With Fosun's YaoPharma To For Novel GLP-1 Obesity Therapy**
- Source: Nasdaq | 20251209T120853 | Bullish | Relevance: 99%
- Pfizer has secured an exclusive global collaboration and license agreement with YaoPharma, a Fosun subsidiary, for YP05002, a GLP-1 receptor agonist in Phase 1 development for chronic weight management. The deal involves an upfront payment of $150 million to YaoPharma, with potential milestone payments up to $1.935 billion and tiered royalties on sales. Pfizer intends to conduct combination studies of YP05002 with other pipeline compounds, including its GIPR antagonist PF-07976016.

**2. Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement**
- Source: The Manila Times | 20251209T122153 | Bullish | Relevance: 98%
-  Fosun Pharma's subsidiary, Yao Pharma, has signed an exclusive collaboration and license agreement with Pfizer Inc., granting Pfizer worldwide rights for the development and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002. Yao Pharma will receive an upfront payment of $150 million and is eligible for up to $1.935 billion in milestone payments, plus tiered royalties on sales. This partnership leverages Pfizer's global reach and Yao Pharma's R&D capabilities to accelerate the development of innovative treatments for metabolic diseases such as chronic weight management and type 2 diabetes.

**3. Pfizer (PFE) Stock; Rises on Strong Dividend Yield and Low Valuation Debate**
- Source: CoinCentral | 20251207T122719 | Somewhat-Bullish | Relevance: 98%
- Pfizer (PFE) shares are gaining investor interest due to a high dividend yield of approximately 6.6% and a historically low valuation. Despite a decline in COVID-related revenue, the company's strong non-COVID product performance and strategic acquisitions like Metsera are reinforcing a post-COVID recovery narrative. Analysts are divided on whether the low valuation represents a deep-value opportunity or a reflection of persistent challenges, with the debate centering on Pfizer's ability to drive long-term growth beyond its value-stock label.

**4. Gamco Investors INC. ET AL Trims Stock Holdings in Pfizer Inc. $PFE**
- Source: MarketBeat | 20251208T114541 | Neutral | Relevance: 98%
-  Gamco Investors INC. ET AL reduced its stake in Pfizer Inc. by 15.5% in Q2, selling 122,695 shares and holding 671,241 shares valued at $16.27 million. Despite this, other institutions like Vanguard, Geode Capital, Norges Bank, and Northern Trust increased their positions, ultimately leaving 68.36% of Pfizer owned by institutional investors. Pfizer also reported an EPS beat, set FY2025 guidance, and offers a 6.6% dividend yield.

**5. Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma**
- Source: Business Wire | 20251209T113311 | Bullish | Relevance: 98%
- Pfizer Inc. has announced an exclusive global collaboration and license agreement with YaoPharma for the development, manufacturing, and commercialization of YP05002, a small molecule GLP-1 receptor agonist in Phase 1 development for chronic weight management. Under the agreement, YaoPharma will receive an upfront payment of $150 million and is eligible for up to $1.935 billion in milestone payments, along with tiered royalties. This collaboration aims to advance Pfizer's portfolio in cardiometabolic diseases and explore combination studies with other pipeline molecules.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Guggenheim | $35 | $33 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Guggenheim | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 12 ($0.22M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 31.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.2%)
- Blackrock Inc.: 8.8% (+0.5%)
- State Street Corpora: 5.3% (+0.9%)
- Geode Capital Manage: 2.3% (+1.2%)
- Morgan Stanley: 1.3% (+6.6%)

### Key Risks

1. Valuation stretched: PEG 3.8x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.77 signals overvaluation risk, limited margin of safety. Quality metrics strong (margin 16%). Balance sheet: $4.0B free cash flow. Analyst sentiment positive (1 raises, avg +6%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $144.0B |
| Beta | 0.42 |
| 52W Range | $20.92 - $27.69 |
| Short Interest | 2.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.77 |
| Forward P/E | 8.2 |
| Current P/E | 8.1 |
| YoY Growth | -1.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -0.2% to -2.5% (-2.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.5pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.03x) but short-term weakness (below SMA20). RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.46% (CS: 39) | Weak |
| RSI_14 | 50.6 | Neutral |
| MACD Histogram | 0.02 | Bullish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 1.005x | Above |
| vs SMA200 | 1.032x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $25.33
- **Stop Loss:** $24.13 (4.7% risk)
- **Target:** $26.53 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 250
- **Position Value:** $6,332.50
- **Portfolio %:** 6.33%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-03 (Est: $0.60)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.63 | $0.87 | +37.4% |
| 2025Q2 | $0.57 | $0.78 | +35.9% |
| 2025Q1 | $0.67 | $0.92 | +36.5% |
| 2024Q4 | $0.46 | $0.63 | +37.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*